Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

1.

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy.

Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, Ray-Coquard I, Sehouli J, Harter P, du Bois A; AGO and GINECO study group.

Ann Oncol. 2012 Oct;23(10):2605-12. Epub 2012 Aug 21.

PMID:
22910840
[PubMed - indexed for MEDLINE]
Free Article
2.

Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.

Nishio S, Katsumata N, Matsumoto K, Tanabe H, Yonemori K, Kouno T, Shimizu C, Ando M, Kamura T, Kasamatsu T, Fujiwara Y.

J Cancer Res Clin Oncol. 2009 Apr;135(4):551-7. doi: 10.1007/s00432-008-0488-x. Epub 2008 Oct 1.

PMID:
18830625
[PubMed - indexed for MEDLINE]
3.

Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.

Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis E, Ioannidis JP.

J Natl Cancer Inst. 2006 Nov 15;98(22):1655-63.

PMID:
17105988
[PubMed - indexed for MEDLINE]
Free Article
4.

Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).

Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück HJ, Kimmig R, Pfisterer J.

Gynecol Oncol. 2009 Aug;114(2):199-205. doi: 10.1016/j.ygyno.2009.04.026. Epub 2009 May 14.

PMID:
19446314
[PubMed - indexed for MEDLINE]
5.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

PMID:
16545208
[PubMed - indexed for MEDLINE]
Free Article
6.

Medical therapy of advanced malignant epithelial tumours of the ovary.

Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.

Forum (Genova). 2000 Oct-Dec;10(4):323-32. Review.

PMID:
11535983
[PubMed - indexed for MEDLINE]
7.

A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer.

Case AS, Rocconi RP, Partridge EE, Straughn JM Jr.

Gynecol Oncol. 2007 Apr;105(1):223-7. Epub 2007 Jan 9.

PMID:
17215031
[PubMed - indexed for MEDLINE]
8.

In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study.

Kim HS, Kim TJ, Chung HH, Kim JW, Kim BG, Park NH, Song YS, Bae DS, Kang SB.

J Cancer Res Clin Oncol. 2009 Nov;135(11):1513-20. doi: 10.1007/s00432-009-0598-0. Epub 2009 May 16.

PMID:
19449027
[PubMed - indexed for MEDLINE]
9.

The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.

Rocconi RP, Matthews KS, Kemper MK, Hoskins KE, Huh WK, Straughn JM Jr.

Gynecol Oncol. 2009 Aug;114(2):242-5. doi: 10.1016/j.ygyno.2009.04.019. Epub 2009 May 17.

PMID:
19447480
[PubMed - indexed for MEDLINE]
10.

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME.

J Clin Oncol. 2008 Dec 1;26(34):5530-6. doi: 10.1200/JCO.2008.16.1703. Epub 2008 Oct 27.

PMID:
18955455
[PubMed - indexed for MEDLINE]
Free Article
11.

Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.

Dizon DS, Dupont J, Anderson S, Sabbatini P, Hummer A, Aghajanian C, Spriggs D.

Gynecol Oncol. 2003 Dec;91(3):584-90.

PMID:
14675681
[PubMed - indexed for MEDLINE]
12.

Can surgical debulking reverse platinum resistance in patients with metastatic epithelial ovarian cancer?

Le T, Faught W, Hopkins L, Fung-Kee-Fung M.

J Obstet Gynaecol Can. 2009 Jan;31(1):42-7.

PMID:
19208282
[PubMed - indexed for MEDLINE]
13.

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.

Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P.

Gynecol Oncol. 2007 Jan;104(1):176-80. Epub 2006 Sep 25.

PMID:
16996584
[PubMed - indexed for MEDLINE]
14.

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer.

Caponigro F, Willemse P, Sorio R, Floquet A, van Belle S, Demol J, Tambaro R, Comandini A, Capriati A, Adank S, Wanders J.

Invest New Drugs. 2005 Jan;23(1):85-9.

PMID:
15528985
[PubMed - indexed for MEDLINE]
15.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
[PubMed - indexed for MEDLINE]
16.

[Ovarian cancer--therapeutic options after the failure of the first line of treatment].

Jabłońska E, Chłosta M, Pawlega J.

Ginekol Pol. 2004 Jan;75(1):58-64. Review. Polish.

PMID:
15112475
[PubMed - indexed for MEDLINE]
17.

Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.

McMeekin DS, Tillmanns T, Chaudry T, Gold M, Johnson G, Walker J, Mannel R.

Gynecol Oncol. 2004 Oct;95(1):157-64.

PMID:
15385126
[PubMed - indexed for MEDLINE]
18.

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A.

J Clin Oncol. 2010 Jul 10;28(20):3323-9. doi: 10.1200/JCO.2009.25.7519. Epub 2010 May 24.

PMID:
20498395
[PubMed - indexed for MEDLINE]
Free Article
19.

Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy.

Eisenhauer EL, Tew WP, Levine DA, Lichtman SM, Brown CL, Aghajanian C, Huh J, Barakat RR, Chi DS.

Gynecol Oncol. 2007 Aug;106(2):381-7. Epub 2007 May 16.

PMID:
17509673
[PubMed - indexed for MEDLINE]
20.

Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.

Gronlund B, Hansen HH, Høgdall C, Engelholm SA.

Cancer. 2002 Oct 15;95(8):1656-62.

PMID:
12365013
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk